Pediatric Cancers | Topics

 
IMX-110 Granted Rare Pediatric Disease Designation by FDA for Rhabdomyosarcoma
January 05, 2022

IMX-110, which was granted a rare pediatric disease designation for patients with rhabdomyosarcoma, is currently being assessed as part of a phase 1b/2a study.

FDA Approves Rituximab Plus Chemo for Select Pediatric Hematologic Malignancies
December 03, 2021

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?
October 22, 2021

In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.

Vincristine/Irinotecan Plus Temozolomide Shows Improved Efficacy in Relapsed/Refractory Rhabdomyosarcoma
October 14, 2021

The addition of temozolomide to vincristine and irinotecan appears to be a new standard of care for adult and pediatric patients with relapsed/refractory rhabdomyosarcoma, according to the European Paediatric Soft Tissue Sarcoma Group.

FDA Grants Rare Pediatric Disease Designation to 177Lu-omburtamab-DTPA for Medulloblastoma
October 11, 2021

Pediatric patients with medulloblastoma may experience benefit from 177Lu-omburtamab-DTPA, which was granted a rare pediatric disease designation by the FDA.

Infusion of HER2-Specific CAR T Cells into Brain or CNS “Feasible” in Pediatric Patients
September 27, 2021

ASTCT recently published an article in their journal Nucleus detailing CAR T-cell in pediatric patients with brain cancer.

Focal 22q11.22 Deletions Associated With Poor Outcomes in Pediatric B-Cell Acute Lymphoblastic Leukemia With IKZF1 Alterations
September 08, 2021

A recent study provides evidence showing that focal 22q11.22 deletions may be correlated with poor outcomes in patients with pediatric B-cell acute lymphoblastic leukemia with alterations in IKZF1.

Vincristine/Dexamethasone Pulse Therapy May be Omitted After 1 Year of Treatment in Pediatric Acute Lymphoblastic Leukemia
September 03, 2021

Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.

Study on Racial and Ethnic Disparities in Pediatric Cancer Identify Difference in Risk Between Patient Subgroups
July 30, 2021

Racial and ethnic disparities in incidence and risk of childhood cancer have been identified across a number of malignancies.

Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?
February 11, 2021

KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.